Am J Med Public Health | Volume 1, Issue 1 | Research Article | Open Access

Trend in Adult 1st Line Antiretroviral Therapy Regimen in Nigeria Antiretroviral Treatment Program: A 20-Months Retrospective Assessment (September-October 2018 to March-April 2020 Reporting Cycle)

Bennett Urama^{1 *}, Nkiru Anonyuo¹ , Anthonia Ibeme¹ , Uzoma Atu² , Taiye Ologun² , Babatunji Odelola³ and Adenike Adelanwa³

¹ USAID Global Health Supply Chain Program-Procurement and Supply Management (GHSC-PSM) Project, Nigeria ² National AIDS and STI Control Program (NASCP), Nigeria ³ United States Agency for International Development (USAID), Nigeria

^*Correspondance to: Bennett Urama 

Abstract

Background: Nigeria Federal Ministry of Health (FMOH) in 2018 adopted World Health Organization (WHO) recommended Dolutegravir (DTG) based Antiretroviral Therapy (ART) regimen Tenofovir/Lamivudine/Dolutegravir (TDF+3TC+DTG) as the preferred 1st line ART for adult and adolescent patients and recommended Tenofovir/Lamivudine/Efavirenz (TDF+3TC+EFV) for women who want to become pregnant. The FMOH also approved gradual transition of eligible adult and adolescent patients from TDF+3TC+EFV and Zidovudine/Lamivudine/Nevirapine (AZT+3TC+NVP) to TDF+3TC+DTG from November 2018. The objective of this analysis was to evaluate the trend in adult 1st line ART regimen following twenty months of implementation of the transition to TDF+3TC+DTG. Method: An analysis was conducted to review retrospective patients per regimen data from September/October 2018 to March/April 2020 reporting cycle. Data was retrieved from Nigeria Health Logistics Management Information System, exported to and analyzed with Microsoft Excel. Results: 85.5% of the patients on adult 1st line regimen were taking TDF+3TC+DTG, 13.3% were on TDF+3TC+EFV, no patient was taking AZT+3TC+NVP while 1.1% was on Abacavir based regimen as of end of April 2020. Conclusion: The evaluation shows that majority of adult and adolescent patients on 1st line ART have been transitioned to TDF+3TC+DTG in line with government recommendation.

Keywords:

HIV/AIDS; Antiretroviral therapy; kidney disease; Dolutegravir; Abacavir; Tenofovir; National HIV/AIDS Indicator and Impact Survey

Citation:

Urama B, Anonyuo N, Ibeme A, Atu U, Ologun T, Odelola B, et al. Trend in Adult 1st Line Antiretroviral Therapy Regimen in Nigeria Antiretroviral Treatment Program: A 20-Months Retrospective Assessment (SeptemberOctober 2018 to March-April 2020 Reporting Cycle). Am J Med Public Health. 2020; 1(2): 1006..